CARLSON DNA Sequencing
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract titled CARLSON DNA Sequencing pertains to a microbiome sequencing service to be provided for the Food and Drug Administration. Classified under NAICS code 541714, this represents a forecast opportunity rather than an active solicitation, indicating planned future procurement in DNA sequencing services related to microbiome analysis. Key points of contact include the Cber Acquisition Liaison reachable via email for program-related inquiries, while the contracting officer details are yet to be determined. Specific details regarding the place of performance, type of set-aside, and solicitation number are not provided at this stage. The forecast was posted on March 11, 2026. This contract will support the FDA's efforts in DNA sequencing, contributing to advanced microbiome research, essential for regulatory science and public health initiatives. Interested parties can monitor updates or access further information through the FDA industry's opportunity forecast portal.
General Info
Agency
NAICS
Place of Performance
USSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
